CorMedix (CRMD) PT Lowered to $19 at JMP Securities, Following Regulatory Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $5.68 +2.16%
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
JMP Securities analyst Jason N. Butler lowered the price target on CorMedix (NASDAQ: CRMD) to $19.00 (from $22.00) while maintaining a Market Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CorMedix reaffirms 2026 revenue guidance, reports $355M cash
- Sprout Social Inc. (SPT) PT Raised to $15 at Stifel
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
